gptkbp:instance_of
|
gptkb:isotope
|
gptkbp:bfsLayer
|
5
|
gptkbp:bfsParent
|
gptkb:Radium-223
|
gptkbp:activities
|
targeting bone metastases
|
gptkbp:application
|
cancer research
treatment of bone metastases
|
gptkbp:class
|
alkaline earth metals
|
gptkbp:clinical_trial
|
ongoing
palliative treatment
|
gptkbp:color
|
silvery-white
|
gptkbp:combatants
|
7.87 Me V
|
gptkbp:composed_of
|
neutron bombardment
alkaline earth metal
|
gptkbp:contraindication
|
severe renal impairment
|
gptkbp:cooling_system
|
high
|
gptkbp:discovered_by
|
gptkb:Frederick_Soddy
|
gptkbp:dissolved
|
low
|
gptkbp:dosage_form
|
55 k Bq/kg body weight
|
gptkbp:duration
|
6 months
|
gptkbp:electronegativity
|
[ Rn] 7s2
|
gptkbp:engine
|
radiotherapy
|
gptkbp:environmental_impact
|
radioactive waste
|
gptkbp:has_public_transport
|
hazardous materials regulations
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ra-223
|
gptkbp:interacts_with
|
other radiopharmaceuticals
|
gptkbp:invention
|
patented
|
gptkbp:is_monitored_by
|
regular blood tests
|
gptkbp:isotopes
|
gptkb:Radium
88
135
|
gptkbp:lifespan
|
11.43 days
|
gptkbp:manager
|
intravenous
|
gptkbp:market
|
available in select markets
|
gptkbp:marketed_as
|
gptkb:Xofigo
|
gptkbp:mass
|
223
|
gptkbp:melting_point
|
1413 ° C
700 ° C
|
gptkbp:mode
|
Rn-219
|
gptkbp:parent
|
gptkb:Ac-227
|
gptkbp:population
|
5.5 g/cm³
|
gptkbp:produced_by
|
neutron activation
isolation from uranium ore
|
gptkbp:provides_information_on
|
NCCN guidelines
|
gptkbp:regulatory_compliance
|
controlled substance
|
gptkbp:roll_rate
|
gptkb:0
|
gptkbp:safety_features
|
radioactivity
radiation safety guidelines
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
radiation exposure
thrombocytopenia
neutropenia
|
gptkbp:storage
|
shielded containers
|
gptkbp:student_enrollment
|
cancer patients with bone metastases
|
gptkbp:symbol
|
gptkb:Ra
|
gptkbp:type_of
|
alpha emitter
|
gptkbp:used_in
|
radiopharmaceuticals
|
gptkbp:water_management
|
radioactive waste disposal
|
gptkbp:year_created
|
1923
|